Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

University of California, San Diego · NCT06820177

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
276
US sites recruiting
3
Study start
April 22, 2025
Record last updated
June 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D\&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D\&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.

Being studied: Tranexamic Acid; Placebo

Conditions: Abortion; Dilation and Evacuation; Hemorrhage; Prophylactic Tranexamic Acid Use; Blood Loss

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Able to understand and sign informed consent
  • Speaks English or Spanish language,
  • Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation

Exclusion Criteria

  • History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)
  • History of coagulopathy
  • Anticoagulant use in the preceding five days
  • Severe renal impairment
  • Chorioamnionitis or sepsis
  • Suspected placenta accreta spectrum
  • Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D\&E
  • Known allergic reaction or hypersensitivity to TXA

Recruiting US locations

  • University of California San Diego

    San Diego, CA 92037

    Site contact: Karen Greiner, MD · 858-329-4464 · familyplanningresearch@health.ucsd.edu

  • Planned Parenthood of the Pacific Southwest

    San Diego, CA 92101

    Site contact: Karen Greiner, MD · 858-329-4464 · familyplanningresearch@health.ucsd.edu

  • Rush University Medical Center

    Chicago, IL 60612

    Site contact: Sadia Haider, MD, MPH · 312-563-6000 · sadia_haider@rush.edu

Study contacts (from the official record)

  • Karen Greiner, MD, MPH · 858-329-4464 · familyplanningresearch@health.ucsd.edu
All healthy volunteers studies in California →
Tranexamic Acid for Second Trimester Dilation and Evacuation and… (NCT06820177) | Bored Studies